This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Life Technologies To Accelerate Adoption Of Next-Generation Sequencing In HLA Through Key Partnerships

CARLSBAD, Calif., April 4, 2012 /PRNewswire/ --  Life Technologies Corporation (NASDAQ: LIFE) today announced that it is working with several partners to develop applications for its Ion Personal Genome Machine (PGM™) system in HLA (human leukocyte antigen) analysis.

HLAs are found on the surfaces of all cells in the body, and individuals vary widely in the combination of HLA sub-types found in their tissues.  Tissue typing by HLA analysis is an essential component of determining organ and bone marrow transplant compatibility between donors and patients.  Accurate typing is needed to reduce the possibility of transplant rejection or the risk of graft versus host disease.  HLAs are coded by a group of genes referred to as the MHC (major histocompatibility complex).

Life Technologies intends to enter into a Sponsored Research Agreement with the Histocompatibility, Immunogenetics, and Disease Profiling Laboratory at the Stanford Department of Pathology.  The researchers include Dolly Tyan, Ph.D., Marcelo Fernandez-Vina, Ph.D., and Matthew Anderson, M.D., Ph.D., who in a joint statement indicated, "Next-generation sequencing technologies offer an exciting new approach to understanding the unmapped genetic variation of the MHC.  We believe the speed, throughput, and automated workflow of a system of this kind may help our efforts to better define this important genetic region for disease associations and clinical transplantation."

Howard Martin, Ph.D. of Addenbrookes Hospital - Cambridge has already begun working with the Ion PGM system and has deployed novel informatics strategies to obtain effective reads of the MHC using existing chemistries.  "The speed and flexibility of the Ion PGM system has enabled us to rapidly develop our HLA sequencing strategy. As read lengths improve, so too does quality and scalability," said Martin, who described his early work in a webinar in October 2011.

"Next generation sequencing offers significant potential to the HLA community. We are particularly interested in the Ion PGM system in light of its technological advantages, rapid throughput, and operational simplicity and we believe it offers an excellent path forward for our laboratory," said Paul Keown, M.D., DSc, Director of Immunology and Head of Nephrology, University of British Columbia.

The transplant diagnostics field represents a $400M global marketplace within the medical sciences.  "Life Technologies is committed to expanding in areas of medical sciences in which genomics can play a critical role in improving patient outcomes," said Ronnie Andrews, president of medical sciences at Life Technologies. "Life believes that the Ion Torrent disruptive technology, including increasing read length and throughput, make it a very promising tool for transplant research."

Life Technologies currently markets the 3500 Capillary Electrophoresis platform and SeCore® kits as a Research Use Only (RUO) product in the United States; these products are also CE-IVD approved in Europe. The Ion PGM system is currently for research purposes only and is not intended for diagnostic uses.



1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,086.63 -26.91 -0.16%
S&P 500 1,987.01 +3.48 0.18%
NASDAQ 4,473.6970 +17.6810 0.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs